Participate in Research
We invite our patients to consider participating in the following studies:
Gynecology Studies
Bacterial Colonization of the Uterus
Dr. Caroline Mitchell
Women who are scheduled to have surgery to remove the uterus are eligible to participate in this study, which is designed to help us understand the normal bacteria in the reproductive tract. All women have bacteria in their vaginas, but we don't know whether these normal bacteria are also present in the uterus. If so, they might play a role in protecting against other infections.
Each woman who enrolls in this study will answer a short questionnaire about her health history and will have samples collected from her uterus after it is removed. We hope that this research will help us understand uterine infections that cause complications like preterm delivery, pelvic inflammatory disease and infertility.
Study coordinator: Evangelyn Nkwopara, evangelc@uw.edu
OSS: Ovarian Symptom Study
Dr. Barbara Goff
Women presenting to the primary care clinics at UWMC-Roosevelt are invited to participate in a study evaluating symptoms and ovarian masses. Women 40 and older who wish to participate fill out a survey about the symptoms they have experienced over the past year as well as some baseline health information.
Women with a specific pattern of symptoms that may be associated with ovarian masses or tumors are offered a transvaginal ultrasound and a blood test that can help us to identify ovarian masses and tumors. These studies are provided free of charge for study participants who qualify to have them but are also voluntary.
Study coordinator: Jeannette Kane, 206.598.2878
DAWN: Depression Attention for Women Now
Dr. Jennifer Melville
Women presenting for care at the Women's Health Care Center at UWMC-Roosevelt and the Women's Clinic at Harborview are invited to participate in a study to improve care for depression. Women 18 and older who wish to participate will be offered a brief screening interview to evaluate presence of current depression symptoms. Eligible women who enroll in the study will be randomly assigned to one of two study groups:
1) the usual care provided by their doctor, or
2) a 12-month depression care management intervention, called DAWN, which offers a choice of management of antidepressant medications and/or therapy.
Women in both study groups will be followed for 18 months, during which they will be asked to complete four study interviews. Participants will be compensated $20 to $30 for each interview, for a total of $100 for completing all four interviews. We hope that this research will improve the care for depression that women receive in women's clinics. Women potentially interested in participating may call the DAWN Study Line at 206.744.3244
Studies of Pregnant Women to Understand Autoimmune Diseases
Dr. J. Lee Nelson, Fred Hutchinson Cancer Research Center
This is a study of how pregnancy affects the immune system. We are interested in the differences between pregnancy in healthy women and pregnancy in women with rheumatoid arthritis.
We are seeking volunteers who have no autoimmune disease as well as those who have rheumatoid arthritis. All volunteers must be pregnant or planning to become pregnant. Primary participants will be asked for blood samples. Blood draws may take place at the Fred Hutchinson Research Center or at a clinic that better suits the participant. We would like to collect blood samples before pregnancy, once during each trimester and at least once after delivery.
Healthy participants will be paid $20 for each blood draw. Along with the blood draws, we would like to obtain a small amount of umbilical cord blood from each participant's baby after delivery. This does not affect the normal process of delivery.
Each participant will fill out a questionnaire about health, family and pregnancy history. Husbands, mothers and previous children will be asked for a cheek swab, a mouth-swish sample or a hair sample in order to collect small amounts of DNA for genetic typing. This information will be compared with results from other families who are participating in the study. For more information about this study, please visit our web site.
Study coordinator: Dawn Stief, 206.667.6850 or 866.648.1917 (toll free) or lnelsonlab@fhcrc.org.
Gynecologic Cancer Studies
A number of multi-center clinical trials are available to gynecologic cancer patients which may allow them access to new and promising therapies.
Phase I trial of ABT-888 PARP inhibitor in combination with gemcitabine and carboplatin for advanced ovarian and breast cancer.
Dr. Heidi Gray
Study coordinator: Bojana Askovich, 206.667.4696
Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Dr. Benjamin Greer
Study coordinator: Monica Dherin, 206.667.4696
Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC#704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Dr. Benjamin Greer
Study coordinator: Monica Dherin, 206.667.4696
Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Dr. Benjamin Greer
Study coordinator: Monica Dherin, 206.667.4696
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Treatment
Dr. Benjamin Greer
Study coordinator: Monica Dherin, 206.667.4696
Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma
Dr. Benjamin Greer
Study coordinator: Monica Dherin, 206.667.4696
Dose Escalating Phase I Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin and Intravenous Paclitaxel and Intravenous Paclitaxel, Intraperitoneal Carboplatin and NCI Supplied Intravenous Bevacizumab (IND#7921) in Patients with Previously Untreated Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Dr. Benjamin Greer
Study coordinator: Monica Dherin, 206.667.4696
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Dr. Benjamin Greer
Study coordinator: Monica Dherin, 206.667.4696
PET and biomarkers in treatment response in advanced ovarian and primary peritoneal cancers (Stage IIIC-IV Previously untreated patients will have biopsy proven carcinoma and are candidates for neoadjuvant chemotherapy.
Dr. Joseph Rajendran
Study coordinator: Ann Wilson, 206.598.2383
Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) with Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Dr. Ron Swensen
Study coordinator: Barbara Buening, 206.667.5153 or 206.2881499
Advanced or recurrent epithelial ovarian cancer SCCA Phase I: MDX-1105 an anti-PDL-1 antibody for selected advanced solid tumors.
Dr. Scott Tykodi
Study coordinator: Bojana Askovich, 206.667.4696